We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
(+13%)
Cap. Flow
+$64.9M
Cap. Flow
% of AUM
3.27%
Top 10 Holdings %
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65
Avg Time Held Equity + Options
4.7
quarters
Top 10 Avg Time Held Equity + Options
5.1
quarters
Top 20 Avg Time Held Equity + Options
6.3
quarters
Avg Time Held Equity only
4.9
quarters
Top 10 Avg Time Held Equity only
5.1
quarters
Top 20 Avg Time Held Equity only
6.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$46.6M |
| 2 |
Puma Biotechnology
PBYI
|
+$41M |
| 3 |
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
|
+$35.9M |
| 4 |
CORI
Corium International, Inc.
CORI
|
+$19M |
| 5 |
Intuitive Surgical
ISRG
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$37.6M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$22.2M |
| 3 |
NEVRO CORP.
NVRO
|
+$20.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$13.3M |
| 5 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$12.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.26% |
| 2 | Miscellaneous | 3.45% |
| 3 | Consumer Staples | 0.19% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Energy | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
CALL
DELISTED
Sage Therapeutics
SAGE
| $21.9M | 1.1% |
275,000
+75,000
| +38% | +$5.42M |
2017 Q1
1 quarter
|
|
|
XLRN
27
DELISTED
Acceleron Pharma
XLRN
| $21.6M | 1.09% |
711,259
+47,402
| +7% | +$1.37M |
2014 Q2
12 quarters
|
|
28
CytomX Therapeutics
CTMX
$519M
| $21.6M | 1.08% |
1,390,381
-140,278
| -9% | -$2.11M |
2016 Q4
2 quarters
|
|
29
DBV Technologies S.A. American Depositary Shares
DBVT
$572M
| $21.1M | 1.06% |
59,177
| – | – |
2015 Q2
8 quarters
|
|
|
KDMN
30
DELISTED
Kadmon Holdings, Inc.
KDMN
| $20.2M | 1.02% |
5,185,847
| – | – |
2016 Q3
3 quarters
|
|
|
31
Intuitive Surgical
ISRG
$149B
| $19.4M | 0.97% |
+186,255
| New | +$17.9M |
2017 Q2
0 quarters
|
|
32
Humana
HUM
$51B
| $18.8M | 0.95% |
78,093
+50,593
| +184% | +$11.5M |
2016 Q4
2 quarters
|
|
|
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
| $17.4M | 0.88% |
+845,000
| New | +$17.3M |
2017 Q2
0 quarters
|
|
34
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.91B
| $17.3M | 0.87% |
226,405
-45,000
| -17% | -$3.78M |
2016 Q4
2 quarters
|
|
35
Cartesian Therapeutics
RNAC
$201M
| $15.8M | 0.8% |
26,578
+21,849
| +462% | +$9.65M |
2016 Q2
4 quarters
|
|
36
Akebia Therapeutics
AKBA
$217M
| $15.8M | 0.8% |
1,100,000
+1,050,376
| +2,117% | +$13.3M |
2015 Q3
7 quarters
|
|
|
AVDL
37
DELISTED
Avadel Pharmaceuticals
AVDL
| $15.8M | 0.79% |
1,429,114
+20,874
| +1% | +$210K |
2016 Q3
3 quarters
|
|
|
MYOK
38
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $14.5M | 0.73% |
553,154
-71,540
| -11% | -$943K |
2015 Q4
6 quarters
|
|
|
ATRS
39
DELISTED
Antares Pharma, Inc.
ATRS
| $13.7M | 0.69% |
4,267,253
+1,350,000
| +46% | +$3.83M |
2016 Q3
3 quarters
|
|
40
DELISTED
Audentes Therapeutics, Inc
BOLD
| $13.5M | 0.68% |
707,500
+700,000
| +9,333% | +$11.2M |
2016 Q3
3 quarters
|
|
41
Aldeyra Therapeutics
ALDX
$53.3M
| $13.4M | 0.68% |
2,885,458
| – | – |
2015 Q1
9 quarters
|
|
|
AVEO
42
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $13.3M | 0.67% |
601,066
+90,185
| +18% | +$710K |
2016 Q2
4 quarters
|
|
43
Jazz Pharmaceuticals
JAZZ
$13.6B
| $13.3M | 0.67% |
85,572
+55,572
| +185% | +$8.5M |
2016 Q4
2 quarters
|
|
|
SIOX
44
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $13.3M | 0.67% |
71,588
+32,838
| +85% | +$5.76M |
2017 Q1
1 quarter
|
|
45
Wave Life Sciences
WVE
$611M
| $12.3M | 0.62% |
662,798
-2,400
| -0.4% | -$51.7K |
2016 Q1
5 quarters
|
|
46
iRhythm Holdings
IRTC
$3.51B
| $12M | 0.6% |
282,857
+11,800
| +4% | +$430K |
2016 Q4
2 quarters
|
|
|
ZYNE
47
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $10.2M | 0.51% |
+100,000
| New | +$1.99M |
2017 Q2
0 quarters
|
|
48
argenx
ARGX
$50.4B
| $9.54M | 0.48% |
+450,000
| New | +$9.37M |
2017 Q2
0 quarters
|
|
49
Ardelyx
ARDX
$813M
| $9.23M | 0.46% |
1,810,581
-75,615
| -4% | -$642K |
2014 Q3
11 quarters
|
|
50
Assembly Biosciences
ASMB
$423M
| $9.12M | 0.46% |
36,819
-18,544
| -33% | -$5.22M |
2015 Q1
9 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2017 Portfolio in Review
As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Perceptive Advisors deployed $64.9M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.
- Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
- Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
- Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
- Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
- Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
- Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
- Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.
Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.